{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T11:15:20Z","timestamp":1788261320051,"version":"build-2803163510"},"reference-count":99,"publisher":"Informa UK Limited","issue":"9","license":[{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"},{"start":{"date-parts":[[2026,8,5]],"date-time":"2026-08-05T00:00:00Z","timestamp":1785888000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/doi.org\/10.1080\/policies-text-data-mining"}],"content-domain":{"domain":["www.tandfonline.com"],"crossmark-restriction":true},"short-container-title":["Expert Opinion on Therapeutic Patents"],"published-print":{"date-parts":[[2026,9,2]]},"DOI":"10.1080\/13543776.2026.2710227","type":"journal-article","created":{"date-parts":[[2026,7,27]],"date-time":"2026-07-27T06:44:06Z","timestamp":1785134646000},"page":"813-848","update-policy":"https:\/\/doi.org\/10.1080\/tandf_crossmark_01","source":"Crossref","is-referenced-by-count":1,"title":["Helicase-primase inhibitors as next-generation anti-HSV agents: from current clinical status to structure\u2013activity relationships and patent coverage"],"prefix":"10.1080","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0512-2774","authenticated-orcid":false,"given":"Christian","family":"Gege","sequence":"first","affiliation":[{"name":"Innovative Molecules GmbH","place":["M\u00fcnchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gerald","family":"Kleymann","sequence":"additional","affiliation":[{"name":"Innovative Molecules GmbH","place":["M\u00fcnchen, Germany"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"301","published-online":{"date-parts":[[2026,8,5]]},"reference":[{"key":"e_1_3_4_3_1","unstructured":"Herpes simplex virus World Health Organization. 2024 Dec 11 [cited 2026 Apr 25]. Available from: https:\/\/www.who.int\/news-room\/fact-sheets\/detail\/herpes-simplex-virus#:~:textKey%20facts main%20cause%20of%20genital%20herpes"},{"key":"e_1_3_4_4_1","doi-asserted-by":"publisher","DOI":"10.1136\/sextrans-2024-056307"},{"key":"e_1_3_4_5_1","volume-title":"Fields virology","author":"Knipe DM","year":"2013","unstructured":"DM Knipe, Howley PM, editors. Fields virology. 6th ed. Philadelphia, USA: Lippincott Williams & Wilkins; 2013.","edition":"6"},{"key":"e_1_3_4_6_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.clinthera.2018.07.006"},{"key":"e_1_3_4_7_1","doi-asserted-by":"publisher","DOI":"10.1098\/rsob.210011"},{"key":"e_1_3_4_8_1","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.86.7.2186"},{"key":"e_1_3_4_9_1","doi-asserted-by":"publisher","DOI":"10.1021\/jm00010a027"},{"key":"e_1_3_4_10_1","doi-asserted-by":"publisher","DOI":"10.1128\/jvi.72.9.6979-6987.1998"},{"key":"e_1_3_4_11_1","doi-asserted-by":"publisher","DOI":"10.1517\/14728222.2013.827663"},{"key":"e_1_3_4_12_1","doi-asserted-by":"publisher","DOI":"10.3390\/v13081547"},{"key":"e_1_3_4_13_1","doi-asserted-by":"publisher","DOI":"10.1021\/mc-2022-vol57.ch13"},{"key":"e_1_3_4_14_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-386"},{"key":"e_1_3_4_15_1","doi-asserted-by":"publisher","DOI":"10.2533\/chimia.1999.297.2"},{"key":"e_1_3_4_16_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.47.6.1798-1804.2003"},{"key":"e_1_3_4_17_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2004.02.007"},{"key":"e_1_3_4_18_1","doi-asserted-by":"publisher","DOI":"10.1039\/C9MD00233B"},{"key":"e_1_3_4_19_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.chembiol.2026.03.006"},{"key":"e_1_3_4_20_1","unstructured":"Kleymann G Fischer R Hendrix M et al. Incompetitive inhibitors of helicase primase. WO2002\/020014."},{"key":"e_1_3_4_21_1","doi-asserted-by":"publisher","DOI":"10.1126\/sciadv.adz1989"},{"key":"e_1_3_4_22_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cell.2025.11.041"},{"key":"e_1_3_4_23_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41564-025-02168-4"},{"key":"e_1_3_4_24_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41421-025-00855-4"},{"key":"e_1_3_4_25_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.13948"},{"key":"e_1_3_4_26_1","unstructured":"Maruho receives manufacturing and marketing approval for a partial change of the indication and dosage\/administration for anti-herpes virus agent \u201camenalief tab. 200mg\u201d for the treatment of recurrent herpes simplex in Japan. Press release from 2023. Feb 24 [cited 2026 Apr 24]. Available from: https\/\/www.maruho.co.jp\/english\/information\/20230224.html"},{"key":"e_1_3_4_27_1","doi-asserted-by":"publisher","DOI":"10.1093\/ofid\/ofac494"},{"key":"e_1_3_4_28_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16608"},{"key":"e_1_3_4_29_1","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jis019"},{"key":"e_1_3_4_30_1","doi-asserted-by":"publisher","DOI":"10.1007\/s12325-017-0642-4"},{"key":"e_1_3_4_31_1","doi-asserted-by":"publisher","DOI":"10.1111\/1346-8138.16027"},{"key":"e_1_3_4_32_1","doi-asserted-by":"publisher","DOI":"10.1002\/jha2.899"},{"key":"e_1_3_4_33_1","doi-asserted-by":"publisher","DOI":"10.1111\/jdv.70279"},{"key":"e_1_3_4_34_1","doi-asserted-by":"publisher","DOI":"10.1177\/09564624251392819"},{"key":"e_1_3_4_35_1","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54775"},{"key":"e_1_3_4_36_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2012.12.006"},{"key":"e_1_3_4_37_1","unstructured":"Aicuris announces pritelivir met primary endpoint in immunocompromised herpes simplex virus-infected patients in phase 3 pivotal trial. Press release from 2025. Oct 16 [cited 2026 Apr 24]. Available from: https:\/\/www.aicuris.com\/press-release\/aicuris-announces-pritelivir-met-primary-endpoint-in-immunocompromised-herpes-simplex-virus-infected-patients-in-phase-3-pivotal-trial\/"},{"key":"e_1_3_4_38_1","doi-asserted-by":"publisher","DOI":"10.1001\/jama.2016.18189"},{"key":"e_1_3_4_39_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1301150"},{"key":"e_1_3_4_40_1","unstructured":"Phaeno therapeutics company website. [cited 2026 Feb 2]. Available from: https\/\/www.phaenothera.com"},{"key":"e_1_3_4_41_1","unstructured":"According to synapse database from Patsnap.com. [cited 2026 Feb 2]."},{"key":"e_1_3_4_42_1","unstructured":"Innovative molecules announces completion of phase 1 program and advancement to phase 2 for oral adibelivir. Press release from 2026. Jan 29 [cited 2026 Apr 25]. Available from: https:\/\/www.innovativemolecules.com\/innovative-molecules-announces-completion-of-phase-1-program-and-advancement-to-phase-2-for-oral-adibelivir"},{"key":"e_1_3_4_43_1","volume-title":"Conference call 2025","unstructured":"Interim results from Phase 1b clinical studies of long-acting helicase-primase inhibitor candidates ABI-1179 and ABI-5366 in recurrent genital herpes. In: Conference call 2025; Dec 8 [cited 2026 Apr 25]. Available from: https:\/\/investor.assemblybio.com\/events\/event-details\/abi-1179-and-abi-5366-interim-phase-1b-results-update"},{"key":"e_1_3_4_44_1","volume-title":"Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global)","author":"Sasadeusz J","year":"2026","unstructured":"Sasadeusz J, Gane EJ, Yan R, et al. Virologic analyses following treatment with ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants seropositive for HSV-2 with recurrent genital herpes. In: Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global); Munich, Germany; 2026 Apr 17\u201321 [cited 2026 May 2]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2026\/04\/Virologic-Analyses-Following-Treatment-With-ABI-5366-a-Novel-Oral-Long-Acting-HSV-HPI-in-Participants-Seropositive-for-HSV-2-With-RGH.pdf"},{"key":"e_1_3_4_45_1","volume-title":"Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global)","author":"Gane EJ","year":"2026","unstructured":"Gane EJ, Sellwood C, Edwards A, et al. The safety and tolerability of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor in participants with recurrent genital herpes. In: Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global); Munich, Germany; 2026 Apr 17\u201321 [cited 2026 May 2]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2026\/04\/The-Safety-and-Tolerability-of-ABI-5366-a-Novel-Oral-Long-Acting-HSV-Helicase-Primase-Inhibitor-in-Participants-With-Recurrent-Genital-Herpes.pdf"},{"key":"e_1_3_4_46_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.7b00183"},{"key":"e_1_3_4_47_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106271"},{"key":"e_1_3_4_48_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1241"},{"key":"e_1_3_4_49_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1138"},{"key":"e_1_3_4_50_1","volume-title":"Innovative molecules, oral presentation at the International Congress on antiviral research (ICAR) 2025","author":"Blank A","year":"2025","unstructured":"Blank A, Bergamino M, Burhenne J, et al. First-in-human, single ascending dose, phase 1 trial to assess safety, tolerability, and pharmacokinetics of IM-250, a helicase-primase inhibitor against herpes simplex virus, in healthy volunteers. In: Innovative molecules, oral presentation at the International Congress on antiviral research (ICAR) 2025. Las Vegas (NV); 2025 Mar 19."},{"key":"e_1_3_4_51_1","volume-title":"Gilead Sciences, late-braking oral presentation at the 38th International Conference on Antiviral Research (ICAR2026)","author":"Fletcher S","year":"2026","unstructured":"Fletcher S. GS-1179 and GS-5366: long-acting oral HSV helicase-primase inhibitors for the treatment of recurrent genital herpes. In: Gilead Sciences, late-braking oral presentation at the 38th International Conference on Antiviral Research (ICAR2026); Prague, Czech Republic; 2026 Apr 28."},{"key":"e_1_3_4_52_1","doi-asserted-by":"publisher","DOI":"10.1002\/cpdd.1358"},{"key":"e_1_3_4_53_1","volume-title":"Aicuris, late-breaking oral presentation at the Tandem Meetings","author":"Papanicolaou GA","year":"2026","unstructured":"Papanicolaou GA, Avery R, Workowski K, et al. Pritelivir demonstrated superior efficacy compared to investigator\u2019s choice treatment for refractory herpes simplex virus infections in immunocompromised patients: PRIOH-1, phase 3 safety and efficacy. In: Aicuris, late-breaking oral presentation at the Tandem Meetings; Salt Lake City (UT); 2026 Feb 7 [cited 2026 May 2]. Available from: http:\/\/www.aicuris.com\/scientific-presentations\/"},{"key":"e_1_3_4_54_1","unstructured":"Molina J-M Workowski K Ramgopal MN et al. 196-pritelivir for refractory HSV infections in immunocompromised patients: results of a Phase III trial. Aicuris oral presentation at the Conference on Retroviruses and opportunistic infections (CROI2026). Denver CO; 2026 Feb 25 [cited 2026 May 2]. Available from: https:\/\/www.aicuris.com\/scientific-presentations\/"},{"key":"e_1_3_4_55_1","unstructured":"Aicuris receives FDA priority review for pritelivir NDA and presents New Phase 3 data at ESCMID. Press release from 2026. Apr 16 [cited 2026 Apr 25]. Available from: https:\/\/www.aicuris.com\/press-release\/aicuris-receives-fda-priority-review-for-pritelivir-nda-and-presents-new-phase-3-data-at-escmid-2026\/"},{"key":"e_1_3_4_56_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106152"},{"key":"e_1_3_4_57_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.cmi.2025.04.011"},{"key":"e_1_3_4_58_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2025.106222"},{"key":"e_1_3_4_59_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jchromb.2026.124995"},{"key":"e_1_3_4_60_1","unstructured":"Alfasigma secures exclusive rights from innovative molecules to parenteral adibelivir for treatment of HSV encephalitis an ultra-rare disease. Press release from 2026. Jan 13 [cited 2026 Apr 25]. Available from: https:\/\/www.alfasigma.com\/corporate\/alfasigma-secures-exclusive-rights-from-innovative-molecules-to-parenteral-adibelivir-for-treatment-of-hsv-encephalitis-an-ultra-rare-disease\/"},{"key":"e_1_3_4_61_1","unstructured":"Gane EJ Schwabe C Wang G et al. ABI-1179 a novel orally administered long-acting HSV helicase-primase inhibitor: interim analysis of safety and pharmacokinetic data from a Phase 1a study in healthy participants. Assembly biosciences presented at the STI & HIV 2025 world congress. Montreal (CA); 2025 Jul 26\u201330 [cited 2026 Apr 25]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2025\/07\/ASMB_STIHIV_2025_Poster_ABI-5366_Phase-1a.pdf"},{"key":"e_1_3_4_62_1","volume-title":"Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global)","author":"Edwards A","year":"2026","unstructured":"Edwards A, Hayter W, Dunsmoor-Su R, et al. The efficacy, safety, and pharmacokinetics of ABI-1179, a novel, oral, long-acting HSV helicase-primase inhibitor for recurrent genital herpes: interim results from a Phase 1b study. In: Assembly Biosciences, poster presentation at Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID Global); Munich, Germany; 2026 Apr 17\u201321 [cited 2026 May 2]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2026\/04\/The-Efficacy-Safety-and-Pharmacokinetics-of-ABI-1179-a-Novel-Oral-Long-Acting-HSV-HPI-for-RGH-Interim-Results-From-a-Phase-1b-Study.pdf"},{"key":"e_1_3_4_63_1","volume-title":"Assembly Biosciences, poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025","author":"Gane EJ","year":"2025","unstructured":"Gane EJ, Schwabe C, Wang G, et al. The safety and pharmacokinetics of ABI-5366, a novel, oral, long-acting HSV helicase-primase inhibitor: interim results from a Phase 1a\/1b study in healthy participants. In: Assembly Biosciences, poster presentation at the Congress of the European Society of Clinical Microbiology and Infectious Diseases (ESCMID) 2025; Vienna, Austria; 2025 Apr 11\u201315 [cited 2026 Apr 25]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2025\/04\/ASMB_ESCMID_2025_Poster_P02465_ABI-5366_Phase-1a.pdf"},{"key":"e_1_3_4_64_1","unstructured":"Gane EJ Sellwood C Edwards A et al. Safety pharmacokinetics and antiviral activity of ABI-5366 a novel oral long-acting HSV helicase-primase inhibitor in subjects with recurrent genital herpes: interim analysis from a phase 1b study. Assembly biosciences 38th Congress of the International Union against sexually transmitted infections (iusti)-europe. Athens (GR); 2025 Oct 9\u201311 [cited 2026 Apr 25]. Available from: https:\/\/www.assemblybio.com\/wp-content\/uploads\/2025\/10\/ASMB_IUSTI_2025_Oral_ABI-5366_Phase-1b-Interim.pdf"},{"key":"e_1_3_4_65_1","doi-asserted-by":"publisher","DOI":"10.1093\/jac\/dkq198"},{"key":"e_1_3_4_66_1","doi-asserted-by":"publisher","DOI":"10.1007\/s13318-018-0481-y"},{"key":"e_1_3_4_67_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2016.12.008"},{"key":"e_1_3_4_68_1","doi-asserted-by":"publisher","DOI":"10.1039\/D2GC04869H"},{"key":"e_1_3_4_69_1","doi-asserted-by":"publisher","DOI":"10.1002\/adfm.201900543"},{"key":"e_1_3_4_70_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm0402-392"},{"key":"e_1_3_4_71_1","doi-asserted-by":"publisher","DOI":"10.2174\/1568012043354242"},{"key":"e_1_3_4_72_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.2c00668"},{"key":"e_1_3_4_73_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.46.6.1766-1772.2002"},{"key":"e_1_3_4_74_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(96)10149-5"},{"key":"e_1_3_4_75_1","doi-asserted-by":"publisher","DOI":"10.3390\/vaccines9060679"},{"key":"e_1_3_4_76_1","doi-asserted-by":"publisher","DOI":"10.3390\/molecules28073220"},{"key":"e_1_3_4_77_1","doi-asserted-by":"publisher","DOI":"10.2217\/imt-2019-0033"},{"key":"e_1_3_4_78_1","doi-asserted-by":"publisher","DOI":"10.1126\/scitranslmed.abf8668"},{"key":"e_1_3_4_79_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2021.105190"},{"key":"e_1_3_4_80_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.antiviral.2023.105733"},{"key":"e_1_3_4_81_1","doi-asserted-by":"publisher","DOI":"10.1128\/AAC.01023-10"},{"key":"e_1_3_4_82_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2022.2113873"},{"key":"e_1_3_4_83_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bmcl.2024.129761"},{"key":"e_1_3_4_84_1","unstructured":"Gilead Sciences exercises option to license Assembly Biosciences\u2019 helicase-primase inhibitor programs for recurrent genital herpes. Press release. 2025 Dec 22 [cited 2026 Apr 25]. Available from: https:\/\/www.gilead.com\/news\/news-details\/2025\/gilead-sciences-exercises-option-to-license-assembly-biosciences-helicase-primase-inhibitor-programs-for-recurrent-genital-herpes"},{"key":"e_1_3_4_85_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2024.2403618"},{"key":"e_1_3_4_86_1","volume-title":"Poster presentation at the 48th Annual International Herpesvirus Workshop","author":"Cho A","year":"2024","unstructured":"Cho A, Nair V, May L, et al. Preclinical characterization of ABI-1179, a potent helicase primase inhibitor for the treatment of recurrent genital herpes. In: Poster presentation at the 48th Annual International Herpesvirus Workshop; P(OR)tland, (OR), USA; 2024 Jul 13\u201317 [cited 2026 Apr 25]. Available from: https:\/\/investor.assemblybio.com\/static-files\/8a408cf9-818d-45fd-ae3e-a242a49e35d4"},{"key":"e_1_3_4_87_1","volume-title":"Poster presentation at the 49th International Herpesvirus Workshop","author":"Contreras H","year":"2025","unstructured":"Contreras H, Yan R, Shen M, et al. ABI-5366 and ABI-1179, two potent, long-acting helicase primase inhibitors for the treatment of recurrent genital herpes. In: Poster presentation at the 49th International Herpesvirus Workshop; Berlin, Germany; 2025 Jul 26\u201330 [cited 2026 Apr 25]. Available from: https:\/\/investor.assemblybio.com\/static-files\/831ade60-291f-4997-817a-d03f0186b37e"},{"key":"e_1_3_4_88_1","doi-asserted-by":"publisher","DOI":"10.1080\/13543776.2025.2548925"},{"key":"e_1_3_4_89_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.9b02092"},{"key":"e_1_3_4_90_1","volume-title":"Poster Presentation at the 47th Annual International Herpesvirus Workshop 2023","author":"Contreras H","year":"2023","unstructured":"Contreras H, Shen M, Schulze G, et al. Pre-clinical characterization of ABI-5366: a highly potent long-acting helicase-primase inhibitor for the treatment of high recurrence genital herpes. In: Poster Presentation at the 47th Annual International Herpesvirus Workshop 2023; Missoula, (MT), USA; 2023 Jul 15\u201319 [cited 2026 Apr 25]. Available from: https:\/\/investor.assemblybio.com\/static-files\/9c962940-cc93-42ad-b433-a4aa64f75807"},{"key":"e_1_3_4_91_1","volume-title":"Poster Presentation at the 48th Annual International Herpesvirus Workshop 2024","author":"Contreras H","year":"2024","unstructured":"Contreras H, Stray K, Azimova D, et al. The helicase-primase inhibitor ABI-5366 is a novel, potent, long-acting inhibitor for the treatment of recurrent genital herpes. In: Poster Presentation at the 48th Annual International Herpesvirus Workshop 2024; P(OR)tland, (OR), USA; 2024 Jul 13\u201317 [cited 2026 Apr 25]. Available from: https:\/\/investor.assemblybio.com\/events\/event-details\/48th-annual-international-herpesvirus-workshop-ihw"},{"key":"e_1_3_4_92_1","doi-asserted-by":"publisher","DOI":"10.1016\/bs.enz.2021.07.003"},{"key":"e_1_3_4_93_1","doi-asserted-by":"publisher","DOI":"10.1021\/acs.jmedchem.5c01625"},{"key":"e_1_3_4_94_1","volume-title":"Oral presentation at the 35th Annual Meeting of the Society of Virology","author":"Villalvazo Guerrero JC","year":"2026","unstructured":"Villalvazo Guerrero JC, Deng L, Richardo T, et al. Novel small chemical compounds inhibiting the HSV-1 helicase-primase complex? In: Oral presentation at the 35th Annual Meeting of the Society of Virology; Heidelberg, Germany; 2026 Mar 20."},{"key":"e_1_3_4_95_1","doi-asserted-by":"publisher","DOI":"10.1007\/s11262-015-1233-6"},{"key":"e_1_3_4_96_1","doi-asserted-by":"publisher","DOI":"10.1128\/aac.01977-25"},{"key":"e_1_3_4_97_1","doi-asserted-by":"publisher","DOI":"10.1080\/21505594.2024.2425744"},{"key":"e_1_3_4_98_1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-024-47940-y"},{"key":"e_1_3_4_99_1","doi-asserted-by":"publisher","DOI":"10.3390\/ddc4030042"},{"key":"e_1_3_4_100_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.bioorg.2025.108437"},{"key":"e_1_3_4_101_1","doi-asserted-by":"publisher","DOI":"10.1136\/bmjopen-2024-088632"}],"container-title":["Expert Opinion on Therapeutic Patents"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2710227","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/full-xml\/10.1080\/13543776.2026.2710227","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.tandfonline.com\/doi\/pdf\/10.1080\/13543776.2026.2710227","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T10:26:26Z","timestamp":1788258386000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.tandfonline.com\/doi\/full\/10.1080\/13543776.2026.2710227"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,5]]},"references-count":99,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9,2]]}},"alternative-id":["10.1080\/13543776.2026.2710227"],"URL":"https:\/\/doi.org\/10.1080\/13543776.2026.2710227","relation":{},"ISSN":["1354-3776","1744-7674"],"issn-type":[{"value":"1354-3776","type":"print"},{"value":"1744-7674","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,5]]},"assertion":[{"value":"The publishing and review policy for this title is described in its Aims & Scope.","order":1,"name":"peerreview_statement","label":"Peer Review Statement"},{"value":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","URL":"http:\/\/www.tandfonline.com\/action\/journalInformation?show=aimsScope&journalCode=ietp20","order":2,"name":"aims_and_scope_url","label":"Aim & Scope"},{"value":"2026-05-05","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-07-23","order":2,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2026-08-05","order":3,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}